key: cord-0720223-tg4bwxvf
authors: Long, S. Wesley; Olsen, Randall J.; Christensen, Paul A.; Bernard, David W.; Davis, James J.; Shukla, Maulik; Nguyen, Marcus; Saavedra, Matthew Ojeda; Yerramilli, Prasanti; Pruitt, Layne; Subedi, Sishir; Kuo, Hung-Che; Hendrickson, Heather; Eskandari, Ghazaleh; Nguyen, Hoang A. T.; Long, J. Hunter; Kumaraswami, Muthiah; Goike, Jule; Boutz, Daniel; Gollihar, Jimmy; McLellan, Jason S.; Chou, Chia-Wei; Javanmardi, Kamyab; Finkelstein, Ilya J.; Musser, James M.
title: Molecular Architecture of Early Dissemination and Massive Second Wave of the SARS-CoV-2 Virus in a Major Metropolitan Area
date: 2020-10-30
journal: mBio
DOI: 10.1128/mbio.02707-20
sha: 120a4168f77f14c93f4b13f8b5970d758b792037
doc_id: 720223
cord_uid: tg4bwxvf

We sequenced the genomes of 5,085 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strains causing two coronavirus disease 2019 (COVID-19) disease waves in metropolitan Houston, TX, an ethnically diverse region with 7 million residents. The genomes were from viruses recovered in the earliest recognized phase of the pandemic in Houston and from viruses recovered in an ongoing massive second wave of infections. The virus was originally introduced into Houston many times independently. Virtually all strains in the second wave have a Gly614 amino acid replacement in the spike protein, a polymorphism that has been linked to increased transmission and infectivity. Patients infected with the Gly614 variant strains had significantly higher virus loads in the nasopharynx on initial diagnosis. We found little evidence of a significant relationship between virus genotype and altered virulence, stressing the linkage between disease severity, underlying medical conditions, and host genetics. Some regions of the spike protein—the primary target of global vaccine efforts—are replete with amino acid replacements, perhaps indicating the action of selection. We exploited the genomic data to generate defined single amino acid replacements in the receptor binding domain of spike protein that, importantly, produced decreased recognition by the neutralizing monoclonal antibody CR3022. Our report represents the first analysis of the molecular architecture of SARS-CoV-2 in two infection waves in a major metropolitan region. The findings will help us to understand the origin, composition, and trajectory of future infection waves and the potential effect of the host immune response and therapeutic maneuvers on SARS-CoV-2 evolution.

experiencing a massive second disease wave that began in late May 2020. To understand SARS-CoV-2 molecular population genomic architecture and evolution and the relationship between virus genotypes and patient features, we sequenced the genomes of 5,085 SARS-CoV-2 strains from these two waves. Our report provides the first molecular characterization of SARS-CoV-2 strains causing two distinct COVID-19 disease waves.

KEYWORDS SARS-CoV-2, COVID-19 disease, genome sequencing, molecular population genomics, evolution, COVID-19 P andemic disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus is now responsible for massive human morbidity and mortality worldwide (1) (2) (3) (4) (5) . The virus was first documented to cause severe respiratory infections in Wuhan, China, beginning in late December 2019 (6) (7) (8) (9) . Global dissemination occurred extremely rapidly and has affected major population centers on most continents (10, 11) . In the United States, the Seattle and the New York City (NYC) regions have been especially important centers of coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2. For example, as of 19 August 2020, there were 227,419 confirmed SARS-CoV-2 cases in NYC, causing 56,831 hospitalizations and 19,005 confirmed fatalities and 4,638 probable fatalities (12) . Similarly, in Seattle and King County, WA, 17,989 SARS-CoV-2positive patients and 696 deaths had been reported as of 18 August 2020 (13) .

The Houston metropolitan area is the fourth largest and most ethnically diverse city in the United States, with a population of approximately 7 million (14) . The 2,400-bed Houston Methodist Hospital health system has seven hospitals and serves a large, multiethnic, and socioeconomically diverse patient population throughout greater Houston (13, 14) . The first COVID-19 case in metropolitan Houston was reported on 5 March 2020, with community spread occurring 1 week later (15) . Many of the first cases in our region were associated with national or international travel in areas known to have SARS-CoV-2 virus outbreaks (15) . A central molecular diagnostic laboratory serving all Houston Methodist hospitals and our very early adoption of a molecular test for the SARS-CoV-2 virus permitted us to rapidly identify SARS-CoV-2-positive patients and interrogate genomic variation among strains causing early infections in the greater Houston area. Our analysis of SARS-CoV-2 genomes causing disease in Houston has continued unabated since early March and is ongoing. Genome sequencing and related efforts were expanded extensively in late May as we recognized that a prominent second wave was under way (Fig. 1) .

Here, we report that SARS-CoV-2 was introduced to the Houston area many times, independently, from diverse geographic regions, with virus genotypes representing genetic clades causing disease in Europe, Asia, and South America and elsewhere in the United States. There was widespread community dissemination soon after COVID-19 cases were reported in Houston. Detection of strains with a Gly614 amino acid replacement in the spike protein, a polymorphism that has been linked to increased transmission and in vitro cell infectivity, increased significantly over time and caused virtually all COVID-19 cases in the massive second disease wave. Patients infected with strains with the Gly614 variant had significantly higher virus loads in the nasopharynx on initial diagnosis. Some naturally occurring single amino acid replacements in the receptor binding domain (RBD) of spike protein resulted in decreased reactivity with a neutralizing monoclonal antibody, consistent with the idea that some virus variants arise due to host immune pressure. the metropolitan area includes 9,444 square miles. The estimated population size of metropolitan Houston is 7 million (https://www.houston.org/houston-data).

Epidemic curve characteristics over two disease waves. The first confirmed case of COVID-19 in the Houston metropolitan region was reported on 5 March 2020 (15) , and the first confirmed case diagnosed in Houston Methodist hospitals was reported on 6 March 2020. The epidemic curve indicated a first wave of COVID-19 cases that peaked around 11 to 15 April, followed by a decline in cases until 11 May. Soon thereafter, the slope of the case curve increased, with a very sharp uptick in confirmed cases beginning on 12 June (Fig. 1B) . We consider 11 May to represent the transition between waves, as this date represents the inflection point of the curve of cumulative new cases and had the absolute lowest number of new cases in the mid-May time period. Thus, for the data presented here, wave 1 is defined as 5 March through 11 May 2020, and wave 2 is defined as 12 May through 7 July 2020. Epidemiologic trends within the Houston Methodist Hospital population were mirrored by data from Harris County and the greater metropolitan Houston region (Fig. 1A ). Through 7 July, 25,366 COVID-19 cases were reported in Houston, 37,776 cases in Harris County, and 53,330 in metropolitan Houston, including 9,823 cases in Houston Methodist Hospital facilities (inpatients and outpatients) (https://www.tmc.edu/ coronavirus-updates/infection-rate-in-the-greater-houston-area/ and https://harriscounty .maps.arcgis.com/apps/opsdashboard/index.html#/c0de71f8ea484b85bb5e fcb7c07c6914).

During the first wave (early March through May 11), 11,476 COVID-19 cases were reported in Houston, including 1,729 cases in the Houston Methodist Hospital system. Early in the first wave (from March 5 through 30 March 2020), we tested 3,080 patient specimens. Of these, 406 (13.2%) samples were positive for SARS-CoV-2, representing 40% (358/898) of all confirmed cases in metropolitan Houston during that time period. As our laboratory was the first hospital-based facility to have the capacity for molecular testing for SARS-CoV-2 on site, our strain samples are likely representative of COVID-19 infections during the first wave.

For the entire study period (5 March through 7 July 2020), we tested 68,418 specimens from 55,800 patients. Of these, 9,121 patients (16.4%) had a positive test result, representing 17.1% (9,121/53,300) of all confirmed cases in metropolitan Houston. Thus, our strain samples are also representative of those responsible for COVID-19 infections in the massive second wave.

To test the hypothesis that, on average, the two waves affected different groups of patients, we analyzed individual patient characteristics (hospitalized and nonhospitalized) in each wave. Consistent with this hypothesis, we found significant differences in the COVID-19 patients in each wave (see Table S1 in the supplemental material). For example, patients in the second wave were significantly younger, had fewer comorbidities, were more likely to be Hispanic/Latino (by self-report), and lived in Zip codes with lower median incomes (Table S1) . A detailed analysis of the characteristics of patients hospitalized in Houston Methodist Hospital facilities in the two waves has recently been published (16) .

SARS-CoV-2 genome sequencing and phylogenetic analysis. To investigate the genomic architecture of the virus across the two waves, we sequenced the genomes of 5,085 SARS-CoV-2 strains dating to the earliest time of confirmed COVID-19 cases in Houston. Analysis of SARS-CoV-2 strains causing disease in the first wave (5 March through May 11) revealed the presence of many diverse virus genomes that, in the aggregate, represent the major clades identified globally to date (Fig. 1B) . Clades G, GH, GR, and S were the four most abundantly represented phylogenetic groups (Fig. 1B) . Strains with the Gly614 amino acid variant in spike protein represented 82% of the SARS-CoV-2 strains in wave 1 and 99.9% in wave 2 (P Ͻ 0.0001; Fisher's exact test) (Fig. 1B) . This spike protein variant is characteristic of clades G, GH, and GR. Importantly, strains with the Gly614 variant represented only 71% of the specimens sequenced in March, the early part of wave 1 (Fig. 1B) . We attribute the decrease in the number of strains with this variant observed in the first 2 weeks of March (Fig. 1B) to fluctuation caused by the relatively fewer COVID-19 cases occurring during that period.

Relating spatiotemporal genome analysis with virus genotypes over two disease waves. We examined the spatial and temporal mapping of genomic data to investigate community spread during wave 1 (Fig. 2) . Rapid and widespread community dissemination occurred soon after the initial COVID-19 cases were reported in Houston. The heterogenous virus genotypes present very early in wave 1 indicate that multiple strains independently entered metropolitan Houston, rather than a single strain having been introduced and then spread. An important observation was that strains of most of the individual subclades were distributed over broad geographic areas (see Fig. S1 in the supplemental material). These findings are consistent with the known ability of SARS-CoV-2 to spread very rapidly from person to person.

Relationship between virus clades, clinical characteristics of infected patients, and additional metadata. It is possible that SARS-CoV-2 genome subtypes have different clinical characteristics, analogous to what is believed to have occurred with Ebola virus (17) (18) (19) and is known to occur for other pathogenic microbes (20) . As an initial examination of this issue in SARS-CoV-2, we tested the hypothesis that patients with disease severe enough to warrant hospitalization were infected with a nonrandom subset of virus genotypes. We also examined the association between virus clades and disease severity based on overall mortality, highest level of required care (intensive care unit [ICU], intermediate care unit [IMU] , inpatient or outpatient), need for mechanical ventilation, and length of stay. There was no simple relationship between virus clades and disease severity using these four indicators. Similarly, there was no simple relationship between virus clades and other metadata, such as sex, age, or ethnicity (Fig. S2) .

Machine learning analysis. Machine learning models can be used to identify complex relationships not revealed by statistical analyses. We built machine learning models to test the hypothesis that virus genome sequence can predict patient outcomes, including mortality, length of stay, level of care, ICU admission, supplemental oxygen use, and mechanical ventilation. Models designed to predict outcomes based on virus genome sequence alone resulted in low F1 scores of less than 50% (0.41 to 0.49), and regression models showed similarly low R 2 values (Ϫ0.01 to (Ϫ0.20) ( Table S2 ). F1 scores near 50% are indicative of classifiers that are performing similarly to random chance. The use of patient metadata alone to predict patient outcome improved the model's F1 scores by 5% to 10% (0.51 to 0.56) overall. The inclusion of patient metadata with virus genome sequence data improved most predictions of outcomes, compared to genome sequence alone, to 50% to 55% F1 overall (0.42 to 0.55) in the models (Table S2 ). The findings are indicative of two possibilities that are not mutually exclusive. First, patient metadata, such as age and sex, may provide more signal for the model to use and thus result in better accuracies. Second, the model's use of single nucleotide polymorphisms (SNPs) may have resulted in overfitting. Most importantly, no SNP predicted a significant difference in outcome. A table of classifier accuracy scores and performance information is provided in Table S2 .

Patient outcome and metadata correlations. Overall, very few metadata categories correlated with patient outcomes (Table S3) . Mortality was independently correlated with increasing age, with a Pearson correlation coefficient (PCC) equal to 0.27. This means that 27% of the variation in mortality can be predicted from patient age. Length of stay correlated independently with increasing age (PCC ϭ 0.20). All other patient metadata correlations to outcomes had PCC values of less than 0.20 (Table S3) .

We further analyzed outcomes correlated to isolates from wave 1 and 2 and to the presence of the Gly614 variant in spike protein. Presence in wave 1 was independently correlated with mechanical ventilation days, overall length of stay, and ICU length of stay, with PCC values equal to 0.20, 0.18, and 0.14, respectively. Importantly, the presence of the Gly614 variant did not correlate with patient outcomes (Table S3) .

Analysis of the nsp12 polymerase gene. The SARS-CoV-2 genome encodes an RNA-dependent RNA polymerase (RdRp; also referred to as Nsp12) used in virus replication (21) (22) (23) (24) . Each of two amino acid substitutions (Phe479Leu and Val556Leu) in RdRp confers significant resistance in vitro to remdesivir, an adenosine analog (25) . Remdesivir is inserted into RNA chains by RdRp during replication, resulting in premature termination of RNA synthesis and inhibition of virus replication. This compound has shown prophylactic and therapeutic benefits against Middle East respiratory syndrome coronavirus (MERS-CoV) and SARS-CoV-2 experimental infection in rhesus macaques (26, 27) . Recent reports indicate that remdesivir has a therapeutic benefit in some patients with hospitalized COVID-19 (28) (29) (30) (31) (32) , leading to its current widespread use in patients worldwide. Thus, it may be important to understand variation in RdRp in large collections of strain samples.

To acquire data about allelic variation in the nsp12 gene, we analyzed our 5,085 virus genomes. The analysis identified 265 SNPs, including 140 nonsynonymous (amino acid-altering) SNPs, resulting in amino acid replacements throughout the protein (Table 1) ( Fig. 3 and 4 ; see also Fig. S3 and S4 ). The most common amino acid change was Pro322Leu, identified in 4,893 (96%) of the 5,085 patient isolates. This amino acid replacement is common in genomes from clades G, GH, and GR, which are distinguished from other SARS-CoV-2 clades by the presence of the Gly614 amino acid change in the spike protein. Most of the other amino acid changes in RdRp were present in relatively small numbers of strains, and some have been identified in other isolates in a publicly available database (33) . Five prominent exceptions included the following amino acid replacements: Ala15Val in 138 strains, Met462Ile in 59 strains, Met600Ile in 75 strains, Thr907Ile in 45 strains, and Pro917Ser in 80 strains. All 75 Met600Ile strains were phylogenetically closely related members of clade G and also had the Pro322Leu amino acid replacement characteristic of this clade (Fig. S3) . These data indicate that the Met600Ile change is likely the evolved state, derived from a precursor strain with the Pro322Leu replacement. Similarly, we investigated phylogenetic relationships among strains with the other four amino acid changes noted above. In all cases, the vast majority of strains with each amino acid replacement were found among individual subclades of strains (Fig. S3) . Importantly, none of the observed amino acid polymorphisms in RdRp were located precisely at two sites known to cause in vitro resistance to remdesivir (25) . Most of the amino acid changes were found to be located distantly from the RNA binding and catalytic sites ( Fig. S4 ; see also Table 1 ). However, replacements at six amino acid residues (Ala442Val, Ala448Val, Ala553Pro/Val, Gly682Arg, Ser758Pro, and Cys812Phe) may potentially interfere with either remdesivir binding or RNA synthesis. Four (Ala442Val, Ala448Val, Ala553Pro/Val, and Gly682Arg) of the six substitution sites are located immediately above the nucleotide-binding site, which is comprised of Lys544, Arg552, and Arg554 residues as shown by structural studies (Fig. 4) . The positions of these four variant amino acid sites are comparable to that of Val556 (Fig. 4) , and a Val556Leu mutation in SARS-CoV was identified to confer resistance to remdesivir in vitro (25) . The other two substitutions (Ser758Pro and Cys812Phe) are inferred to be located either at, or in the immediate proximity of, the catalytic active site, which is comprised of three contiguous residues (Ser758, Asp759, and Asp760). A proline substitution that we identified at Ser758 (Ser758Pro) is likely to negatively impact RNA synthesis. Although Cys812 is not directly involved in the catalysis of RNA synthesis, it is only 3.5 Å away from Asp760. The introduction of the bulkier phenylalanine substitution at Cys812 (Cys812Phe) may impair RNA synthesis. Consequently, these two substitutions are expected to detrimentally affect virus replication or fitness.

Analysis of the gene encoding the spike protein. The densely glycosylated spike protein of SARS-CoV-2 and of its close coronavirus relatives binds directly to host cell angiotensin-converting enzyme 2 (ACE2) receptors to enter host cells (34) (35) (36) . Thus, the spike protein is a major translational research target, including intensive vaccine and therapeutic antibody research . Analysis of the gene encoding the spike protein identified 470 SNPs, including 285 that produce amino acid changes ( Table 2 ; see also Fig. 5) . Forty-nine of these replacements (V11A, T51A, W64C, I119T, E156Q, S205A,  D228G, L229W, P230T, N234D, I235T, T274A, A288V, E324Q, E324V, S325P, S349F,  S371P, S373P, T385I, A419V, C480F, Y495S, L517F, K528R, Q628E, T632I, S708P, T719I,  P728L, S746P, E748K, G757V, V772A, K814R, D843N, S884A, M902I, I909V, E918Q, S982L,  M1029I, Q1142K We mapped the location of amino acid replacements onto a model of the full-length spike protein (34, 64) and observed that the substitutions are found in each subunit and domain of the spike (Fig. 6) . However, the distribution of amino acid changes is not uniform throughout the protein regions. For example, compared to some other regions of the spike protein, the RBD has relatively few amino acid changes, and the frequency of strains with these substitutions is low, each occurring in fewer than 10 isolates. This finding is consistent with the functional constraints on RBD to mediate interaction with ACE2. In contrast, the periphery of the S1 subunit amino-terminal domain (NTD) contains a dense cluster of substituted residues, with some single amino acid replacements found in 10 to 20 isolates (Table 2 ; see also Fig. 5 and 6) . Clustering of amino acid changes in a distinct region of the spike protein may be a signal of positive selection. Inasmuch as infected patients make antibodies against the NTD, we favor the idea that host immune selection is among the forces contributing to some of the amino acid variation in this region. One NTD substitution, H49Y, was found in 142 isolates. This position is not well exposed on the surface of the NTD and likely does not represent a result of immune pressure. The same is true for another highly represented substitution, F1052L. This substitution was observed in 167 isolates, and F1052 is buried within the core of the S2 subunit. The substitution observed most frequently in the spike protein in our sample is D614G, a change observed in 4,895 of the isolates. As noted above, strains with the Gly614 variant significantly increased in frequency in wave 2 compared to wave 1.

As observed with RdRp, the majority of strains with each single amino acid change in the spike protein were found on a distinct phylogenetic lineage (Fig. S5) , indicating identity by descent. A prominent exception is the Leu5Phe replacement that is present in all major clades, suggesting that this amino acid change arose multiple times independently or very early in the course of SARS-CoV-2 evolution. Finally, we note that examination of the phylogenetic distribution of strains with multiple distinct amino acid replacements at the same site (e.g., Arg21Ile/Lys/Thr, Ala27Ser/Thr/Val, etc.) re- The side chains of amino acids participating in nucleotide binding (Lys544, Arg552, and Arg554) are shown as balls and sticks and colored light blue. A remdesivir molecule incorporated into the nascent RNA is shown as balls and sticks and colored light pink. The RNA is shown as a blue cartoon, and bases are shown as sticks. The positions of C␣ atoms of amino acids identified in this study are shown as red and green spheres and labeled. The amino acids that are shown as red spheres are located above the nucleotide binding site, whereas Cys812 located at the catalytic site is shown as a green sphere. The side chain of active site residue Ser758 is shown as ball and sticks and colored yellow. The location of C␣ atoms of remdesivir resistance-conferring amino acid Val556 is shown as a blue sphere and labeled. C13T  L5F  S1  11  25  36  21578  G16T  V6F  S1  1  1  21587  C25T  P9S  S1  2  2  21588  C26T  P9L  S1  1  1  2  21594  T32C  V11A  S1  1  1  21597 C35T S12F S1 -NTD  1  1  21846  C284T  T95I  S2-NTD  1  10  11  21852  A290G  K97R  S2-NTD  1  1  21855  C293T  S98F  S2-NTD  1  2  3  21861  T299C  I100T  S2-NTD  2  2  21918  T356C  I119T  S2-NTD  1  1  21930  C368T  A123V  S2-NTD  1  1  21941  G379T  V127F  S2-NTD  1  1  21942  T380C  V127A  S2-NTD  4  4  21974 G412T 1  1  22382  A820G  T274A  S2-NTD  1  1  22398  A836T  Y279F  S2-NTD  1  1  22408  T846G  N282K  S2-NTD  1  1  22425  C863T  A288V  S2-NTD  1  1  22430  G868T  D290Y  S2-NTD  1  1  22484  G922T  V308L  S1  3  3  22487  G925C  E309Q  S1  1  1  22532  G970C  E324Q  S1  1  1  22533  A971T  E324V  S1  1  1  22535  T973C  S325P  S1  1  1  22536  C974T  S325F  S1  1  1  22550  C988T  P330S  S2-RBD  2  2  22574  T1012C  F338L  S2-RBD  1  1  22608 C1046T

(Continued on next page) C1873T  H625Y  S1  1  1  23439  C1877T  A626V  S1  1  1  23444  C1882G  Q628E  S1  7  7  23453  C1891T  P631S  S1  1  1  23457  C1895T  T632I  S1  1  1  23481  C1919T  S640F  S1  1  42  43  23486  G1924T  V642F  S1  1  1  23502  C1940T  A647V  S1  1  1  23536  C1974A  N658K  S1  4  4  23564  G2002T  A668S  S1  1  1  23586  A2024G  Q675R  S1  14  14  23587  G2025C  Q675H  S1  1  1  23587  G2025T  Q675H  S1  4  4  23589  C2027T  T676I  S1  1  2  3  23593  G2031T  Q677H  S1  1  1  2  23595  C2033T  T678I  S1  1  1  23624  G2062T  A688S  S2  4  4  23625  C2063T  A688V  S2  16  16  23655  C2093T  S698L  S2  1  1  23664  C2102T  A701V  S2  21  21  23670  A2108G  N703S  S2  1  1  23679  C2117T  A706V  S2  1  1  23684  T2122C  S708P  S2  1  1  23709  C2147T  T716I  S2  1  1  23718  C2156T  T719I  S2  1  1  23745  C2183T  P728L  S2  1  1  23755  G2193T  M731I  S2  3  1  4  23798  T2236C  S746P  S2  1  1  23802  C2240T  T747I  S2  1  1  23804  G2242A  E748K  S2  1  1  23832  G2270T  G757V  S2  1  1  23856  G2294T  R765L  S2  1  1  23868  G2306T  G769V  S2  3  3  23873  G2311T  A771S  S2  8  8  23877  T2315C  V772A  S2  1  1  23895  C2333T  T778I  S2  1  1  23900  G2338C  E780Q  S2  1  1  23936  C2374T  P792S  S2  1 T859I  S2  5  5  24141  T2579C  V860A  S2  1  1  24170  A2608G  I870V  S2  3  3  24188  G2626T  A876S  S2  1  1  24197  G2635T  A879S  S2  31  31  24198  C2636T  A879V  S2  1  1  24212  T2650G  S884A  S2  11  11  24237  C2675T  A892V  S2  1  1  24240  C2678T  A893V  S2  1  1  24268  G2706T  M902I  S2  1  1  24287  A2725G  I909V  S2-HR1  2  2  24314  G2752C  E918Q  S2-HR1  1  1  24328  G2766C  L922F  S2-HR1  2  2  24348  G2786T  S929I  S2-HR1  1  1  24356  G2794T  G932C  S2-HR1  1  1  24357  G2795T  G932V  S2-HR1  1  1  24368  G2806A  D936N  S2-HR1  3  3  24368  G2806C  D936H  S2-HR1  1  1  24368  G2806T  D936Y  S2-HR1  3  4  7  24374  C2812T  L938F  S2-HR1  3  3  24378  C2816T  S939F  S2-HR1  4  4  24380  T2818G  S940A  S2-HR1  5  5  24389  A2827G  S943G  S2-HR1  6  6  24463  C2901A  S967R  S2-HR1  2  2  24507  C2945T  S982L  S2-HR1  1  1  24579  C3017T  T1006I  S2-CH  1  1  24588  C3026G  T1009S  S2-CH  1  1  24621  C3059T  A1020V  S2-CH  1  1  24638  G3076T  A1026S  S2-CH  2  2  24642  C3080T  T1027I  S2-CH  5  5  24649  G3087T  M1029I  S2-CH  1  1  24710  A3148T  M1050L  S2  1  1  24710  A3148G  M1050V  S2  1  1  2  24712  G3150T  M1050I  S2  2  2  24718  C3156A  F1052L  S2  1  166  167  24770  G3208T  A1070S  S2  2  2  24794  G3232T  A1078S  S2-CD  3  2  5  24812  G3250T  D1084Y  S2-CD  1  29  30  24834  G3272T  R1091L  S2-CD  1  1  24867  G3305T  W1102L  S2-CD  1  1  24872  G3310T  V1104L  S2-CD  1  1  24893  G3331C  E1111Q  S2-CD  2  2  24897  C3335T  P1112L  S2-CD  2  2  4  24912  C3350T  T1117I  S2-CD  1  1  24923  T3361C  F1121L  S2-CD  2  2  24933  G3371T  G1124V  S2-CD  1  2  3 (Continued on next page) Two Waves of COVID-19 Disease in Houston, Texas vealed that they were commonly found in different genetic branches, consistent with independent origin (Fig. S5) .

Cycle threshold (C T ) comparison of SARS-CoV-2 strains with either the Asp614 or Gly614 amino acid replacements in spike protein. It has been reported that patients infected with strains having the spike protein Gly614 variant have, on average, higher virus loads on initial diagnosis (65) (66) (67) (68) (69) . To determine if this is the case in Houston strains, we examined the cycle threshold (C T ) for every sequenced strain that was detected from a patient specimen using the SARS-CoV-2 assay done by the use of a Hologic Panther instrument. We identified a significant difference (P Ͻ 0.0001) between the mean C T values determined for strains with an Asp614 (n ϭ 102) or Gly614 (n ϭ 812) variant of the spike protein (Fig. 7) . Strains with Gly614 had a C T value G3621T  E1207D  S2  1  1  25186  G3624T  Q1208H  S2  1  1  25217  G3655T  G1219C  S2  1  3  4  25234  G3672T  L1224F  S2  1  1  25241  A3679G  I1227V  S2  1  1  25244  G3682T  V1228L  S2  2  2  25249  G3687T  M1229I  S2  1  1  25249  G3687C  M1229I  S2  2  2  25250  G3688A  V1230M  S2  1  1  25266  G3704T  C1235F  S2  4  4  25273  G3711T  M1237I  S2  2  2  25284  G3722T  C1241F  S2  1  1  25287  G3725T  S1242I  S2  4  4  25297  G3735T  K1245N  S2  1  1  25301  T3739G  C1247G  S2  1  1  25302  G3740T  C1247F  S2  4  4  25305  G3743T  C1248F  S2  2  2  25317  C3755T  S1252F  S2  1  1  25340  G3778T  D1260Y  S2  2  2  25350  C3788T  P1263L  S2  1  2  3  25352  G3790T  V1264L  S2  1  1  25365  T3803C  V1268A  S2  1 significantly lower than that calculated for strains with the Asp614 variant, indicating that the patients infected with the Gly614 strains had, on average, higher virus loads on initial diagnosis than the patients infected by strains with the Asp614 variant (Fig. 7) . This observation is consistent with the conjecture that, on average, strains with the Gly614 variant are better able to disseminate (65) (66) (67) (68) (69) .

The RBD of spike protein binds the ACE2 surface receptor and is also targeted by neutralizing antibodies (35, 36, 40, 42-45, 47-61, 70) . Thus, single amino acid replacements in this domain may have functional consequences that enhance virus fitness. To begin to test this idea, we expressed spike variants with the Asp614Gly replacement and 13 clinical RBD variants Table S4A and B). All RBD variants were cloned into an engineered spike protein construct that stabilizes the perfusion state and increases overall expression yield (spike-6P, here referred to as spike) (63). The C␣ atom of residues found to be substituted in one or more virus isolates identified in this study is shown as a sphere on the ribbon representation. Residues found to be substituted in 1 to 9 isolates are colored tan, those substituted in 10 to 99 isolates yellow, those substituted in 100 to 999 isolates red (H49Y and F1052L), and those substituted in Ͼ1,000 isolates purple (D614G). The surface of the amino-terminal domain (NTD) that is distal to the trimeric axis has a high density of substituted residues. RBD, receptor binding domain. Two Waves of COVID-19 Disease in Houston, Texas ® We first assessed the biophysical properties of spike-Asp614Gly, an amino acid polymorphism that is common globally and that was present at significantly increased levels in our wave 2 strain isolates. Pseudotyped viruses expressing spike-Gly614 have higher infectivity for host cells in vitro than spike-Asp614 (65, 66, 68, 71, 72) . The higher infectivity of spike-Gly614 is correlated with increased stability and incorporation of the spike protein into the pseudovirion (72). We observed a higher expression level (Fig. 8A and B) and increased thermostability for the spike protein construct containing this variant ( Fig. 8C and D) . The size exclusion chromatography (SEC) elution profile of spike-Asp614 was indistinguishable from that of spike-Gly614, consistent with a trimeric conformation (Fig. 8A) . These results are broadly consistent with higher-resolution structural analyses of both spike variants.

Next, we purified and biophysically characterized 13 RBD mutants that each contain Gly614 and one additional single amino acid replacement that we identified by genome sequencing of our clinical samples (Table S4C ). All variants eluted as trimers, indicating that the global structure remained intact ( Fig. 8; see also Fig. S6 ). However, several variants had reduced expression levels and virtually all had decreased thermostability relative to the variant that had only a single D614G amino acid replacement (Fig. 8D) . The A419V and A522V mutations were especially deleterious, reducing yield and precluding further downstream analysis (Fig. 8B) . We next assayed the affinity of the 11 highest-expressing spike variants for ACE2 receptor and the neutralizing monoclonal antibody CR3022 via enzyme-linked immunosorbent assays (ELISAs) (Fig. 8E to G; see also Table S4C ). Most variants retained high affinity for the ACE2 surface receptor. However, importantly, three RBD variants (F338L, S373P, and R408T) had substantially reduced affinity for CR3022, a monoclonal antibody that disrupts the spike protein homotrimerization interface (62, 73) . Notably, the S373P mutation is one amino acid away from the epitope recognized by CR3022 (62) . These results are consistent with the interpretation that some RBD mutants arising in COVID-19 patients may have an increased ability to escape humoral immune pressure but otherwise retain strong ACE2 binding affinity.

In this work, we analyzed the molecular population genomics, sociodemographic, and medical features of two waves of COVID-19 disease occurring in metropolitan Houston, TX, between early March and early July 2020. We also studied the biophysical and immunologic properties of some naturally occurring single amino acid changes in the spike protein RBD identified by sequencing the 5,085 genomes. We discovered that the first COVID-19 wave was caused by a heterogenous array of virus genotypes assigned to several different clades. The majority of cases in the first wave were related to strains that caused widespread disease in European and Asian countries, as well as other localities. We conclude that the SARS-CoV-2 virus was introduced into Houston many times independently, likely by individuals who had traveled to or from different parts of the world, including other communities in the United States. In support of this conclusion, the first cases in metropolitan Houston were associated with a travel history to a region with a known high incidence of COVID-19 (15) . The data are consistent with the fact that Houston is a large international city characterized by a multiethnic population and is a prominent transport hub with direct flights to major cities globally.

The second wave of COVID-19 cases is also characterized by SARS-CoV-2 strains with diverse genotypes. Virtually all cases in the second and ongoing disease wave had been caused by strains with the Gly614 variant of spike protein (Fig. 1B) . Our data unambiguously demonstrate that strains with the Gly614 variant increased significantly in frequency in wave 2 relative to wave 1 in the Houston metropolitan region. This shift occurred very rapidly, in a matter of just a few months. Amino acid residue Asp614 is located in subdomain 2 (SD-2) of the spike protein and forms a hydrogen bond and electrostatic interaction with two residues in the S2 subunit of a neighboring protomer. Replacement of aspartate with glycine would eliminate both interactions, thereby substantively weakening the contact between the S1 and S2 subunits. We previously Long et al. ® speculated (74) that this weakening produces a more highly fusogenic spike protein, as S1 must first dissociate from S2 before S2 can refold and mediate fusion of virus and cell membranes. Stated another way, virus strains with the Gly614 variant may be better able to enter host cells, potentially resulting in enhanced spread. Consistent with this idea, Korber et al. (65) showed that the Gly614 variant grows to a higher titer as pseudotyped virions. On initial diagnosis, infected individuals had lower real-time PCR (RT-PCR) cycle threshold values, suggesting higher upper respiratory tract viral loads. Our data (Fig. 7) are fully consistent with the finding, previously reported by Zhang et al. (72) , that pseudovirus with the 614Gly variant infected ACE2 receptor-expressing cells more efficiently than the 614Asp variant. Similar results have been described by Hu et al. (66) and Lorenzo-Redondo et al. (67) . Plante et al. (75) recently studied isogenic mutant SARS-CoV-2 strains with either the 614Asp or 614Gly variant and found that the 614Gly variant virus showed significantly increased replication in human lung epithelial cells in vitro and increased infectious titers in nasal and tracheal washes obtained from experimentally infected hamsters. These results are consistent with the idea that the 614Gly variant bestows increased virus fitness in the upper respiratory tract (75) .

Additional work is needed to investigate the potential biomedical relevance and public health importance of the Asp614Gly polymorphism, including but not limited to virus dissemination, overall fitness, impact on clinical course and virulence, and development of vaccines and therapeutics. Although it is possible that stochastic processes alone may account for the rapid increase in COVID-19 disease frequency caused by viruses containing the Gly614 variant, we do not favor that interpretation, in part because of the cumulative weight of the epidemiologic, human RT-PCR diagnostics data, in vitro experimental findings, and animal infection studies using isogenic mutant virus strains (65-69, 72, 75) . In addition, if stochastic processes are solely responsible, we believe it is difficult to explain essentially simultaneous increases in frequency of the Gly614 variant in genetically diverse viruses in three distinct clades (G, GH, and GR) in a geographically large metropolitan area with 7 million ethnically diverse people. Regardless, more research on this important topic is warranted.

The diversity present in our 1,026 virus genomes from the first disease wave contrasts somewhat with data reported by Gonzalez-Reiche et al., who studied 84 SARS-CoV-2 isolates causing disease in patients in the New York City region (11) . Those investigators concluded that the vast majority of disease was caused by progeny of strains imported from Europe. Similarly, Bedford et al. (10) reported that much of the COVID-19 disease in the Seattle, WA, area was caused by strains that are progeny of a virus strain recently introduced from China. Some aspects of our findings are similar to those reported recently by Lemieux et al. on the basis of analysis of strains causing disease in the Boston area (76) . Our findings, like theirs, highlight the importance of multiple importation events of genetically diverse strains in the epidemiology of COVID-19 disease in this pandemic. Similarly, Icelandic and Brazilian investigators documented that SARS-CoV-2 was imported by individuals traveling to or from many European and other countries (77, 78) .

The virus genome diversity and large sample size in our study permitted us to test the hypothesis that distinct virus clades were nonrandomly associated with hospitalized COVID-19 patients or disease severity. We did not find evidence to support this hypothesis, but our continuing study of COVID-19 cases accruing in the second wave will further improve statistical stratification.

We used machine learning classifiers to identify if any SNPs contribute to increased infection severity or otherwise affect virus-host outcomes. The models could not be trained to accurately predict these outcomes from the available virus genome sequence data. This may have been due to sample size or class imbalance. However, we do not favor this interpretation. Rather, we think that the inability to identify particular virus SNPs predictive of disease severity or infection outcome likely reflects the substantial heterogeneity in underlying medical conditions and treatment regimens of the COVID-19 patients studied here. An alternative but not mutually exclusive hypothesis is that patient genotypes play an important role in determining virus-human interac-tions and in the resulting pathology. Although some evidence has been presented in support of this idea (79, 80) , available data suggest that in the aggregate, host genetics does not play an overwhelming role in determining outcome in the great majority of adult patients, once virus infection is established.

Remdesivir is a nucleoside analog reported to have activity against MERS-CoV, a coronavirus related to SARS-CoV-2. Recently, several studies have reported that remdesivir shows promise in treating COVID-19 patients (28) (29) (30) (31) (32) , leading the FDA to issue an emergency use authorization. Because in vitro resistance of SARS-CoV to remdesivir has been reported to be caused by either of two amino acid replacements in RdRp (Phe479Leu or Val556Leu), we interrogated our data for polymorphisms in the nsp12 gene. Although we identified 140 different inferred amino acid replacements in RdRp in the 5,085 genomes analyzed, none of these were located precisely at the two positions associated with in vitro resistance to remdesivir. Inasmuch as remdesivir is now being deployed widely to treat COVID-19 patients in Houston and elsewhere, our findings suggest that the majority of SARS-CoV-2 strains currently circulating in our region should be susceptible to this drug.

The amino acid replacements Ala442Val, Ala448Val, Ala553Pro/Val, and Gly682Arg that we identified occur at sites that, intriguingly, are located directly above the nucleotide substrate entry channel and nucleotide binding residues Lys544, Arg552, and Arg554 (21, 22) (Fig. 4) . One possibility is that substitution of the smaller alanine or glycine residues with the bulkier side chains of Val/Pro/Arg may impose structural constraints for the modified nucleotide analog to bind and may thereby disfavor remdesivir binding. This, in turn, may lead to reduced incorporation of remdesivir into the nascent RNA, increased fidelity of RNA synthesis, and, ultimately, drug resistance. A similar mechanism has been proposed for a Val556Leu change (22) .

We also identified one strain with a Lys477Asn replacement in RdRp. This substitution is located close to a Phe479Leu replacement reported to have produced partial resistance to remdesivir in vitro in SARS-CoV patients from 2004, although the amino acid positions are numbered differently in SARS-CoV and SARS-CoV-2. Structural studies have suggested that this amino acid is surface exposed and is distant from known key functional elements. Our observed Lys477Asn change is also located in a conserved motif described as a finger domain of RdRp ( Fig. 3 and 4) . One speculative possibility is that Lys477 is involved in binding an as-yet-unidentified cofactor such as Nsp7 or Nsp8, an interaction that could modify nucleotide binding and/or fidelity at a distance. These data warrant additional study in larger patient cohorts, especially in individuals treated with remdesivir.

Analysis of the gene encoding the spike protein identified 285 polymorphic amino acid sites relative to the reference genome, including 49 inferred amino acid replacements not present in available databases as of 19 August 2020. Importantly, 30 amino acid sites in the spike protein had two or three distinct replacements relative to the reference strain. The occurrence of multiple variants at the same amino acid site is one characteristic that may suggest functional consequences. These data, coupled with structural information available for spike protein, raise the possibility that some of the amino acid variants have functional consequences, including, for example, altered serologic reactivity as shown here. These data permit generation of many biomedically relevant hypotheses now under study.

A recent study reported that RBD amino acid changes could be selected in vitro using a pseudovirus neutralization assay and sera obtained from convalescent plasma or monoclonal antibodies (81) . The amino acid sites included positions V445 and E484 in the RBD. Note that variants G446V and E484Q were present in our patient samples. However, these mutations retain high affinity to CR3022 (Fig. 8F and G) . The highresolution structure of the RBD/CR3022 complex shows that CR3022 makes contacts to residues 369 to 386, 380 to 392, and 427 to 430 of RBD (73) . Although there is no overlap of CR3022 and ACE2 receptor epitopes, CR3022 is able to neutralize the virus through an allosteric effect. We found that the Ser373Pro change, which is located within the CR3022 epitope, resulted in reduced affinity to CR3022 (Fig. 8F and G) . The F338L and R408T mutations, although not found directly within the interacting epitope, also display reduced binding to CR3022. Other investigators (81) using in vitro antibody selection identified a change at amino acid site S151 in the N-terminal domain, and we found mutations S151N and S151I in our patient samples. We also note that two variant amino acids (Gly446Val and Phe456Leu) that we identified were located in a linear epitope found to be critical for a neutralizing monoclonal antibody described recently by Li et al. (82) .

In the aggregate, these findings suggest that mutations emerging within the spike protein at positions within and proximal to known neutralization epitopes may result in escape from antibodies and other therapeutics currently under development. Importantly, our study did not reveal that these mutant strains had disproportionately increased in number over time. The findings may also bear on the occurrence of multiple amino acid substitutions at the same amino acid site that we identified in this study, commonly a signal of selection. In the aggregate, the data support a multifaceted approach to serological monitoring and biologics development, including the use of monoclonal antibody cocktails (45, 46, 83) .

Concluding statement. Our work represents analysis of the largest sample to date of SARS-CoV-2 genome sequences from patients in one metropolitan region in the United States. The investigation was facilitated by the fact that we had rapidly assessed a SARS-CoV-2 molecular diagnostic test in January 2020, more than a month before the first COVID-19 patient was diagnosed in Houston. In addition, our large health care system has seven hospitals and many facilities (e.g., outpatient care centers, emergency departments) located in geographically diverse areas of the city. We also provide reference laboratory services for other health care entities in the Houston area. Together, our facilities serve patients of diverse ethnicities and socioeconomic statuses. Thus, the data presented here likely reflect a broad overview of virus diversity causing COVID-19 infections throughout metropolitan Houston. We previously exploited these features to study influenza virus and Klebsiella pneumoniae dissemination in metropolitan Houston (84, 85) . We acknowledge that not every "twig" of the SARS-CoV-2 evolutionary tree in Houston is represented in these data. The samples studied are not comprehensive with respect to the entire metropolitan region. For example, it is possible that our strain samples are not fully representative of individuals who are indigent, homeless, or of very low socioeconomic status. In addition, although the strain sample size was relatively large compared to other studies, the samples represented only about 10% of all COVID-19 cases in metropolitan Houston documented in the study period. In addition, some patient samples contained relatively small amounts of virus nucleic acid and did not yield adequate sequence data for high-quality genome analysis. Thus, our data likely underestimate the extent of genome diversity present among SARS-CoV-2 strains causing COVID-19 and will not identify all amino acid replacements in the virus in this geographic region. It will be important to sequence and analyze the genomes of additional SARS-CoV-2 strains causing COVID-19 cases in the ongoing second massive disease wave in metropolitan Houston, and such studies are under way. Data of this type will be especially important to have if a third wave and subsequent waves were to occur in metropolitan Houston, as it could provide insight into molecular and epidemiologic events contributing to them.

The genomes reported here are an important data resource that will underpin our ongoing study of SARS-CoV-2 molecular evolution and dissemination and medical features of COVID-19 in Houston. As of 19 August 2020, there were 135,866 reported cases of COVID-19 in metropolitan Houston, and the number of cases is increasing daily. Although the full array of factors contributing to the massive second wave in Houston is not known, it is possible that the potential for increased transmissibility of SARS-CoV-2 with the Gly614 amino acid replacement may have played a role, as well as changes in behavior associated with the Memorial Day and July 4th holidays and relaxation of some of the social constraints imposed during the first wave. The availability of extensive virus genome data dating from the earliest reported cases of COVID-19 in metropolitan Houston, coupled with the database we have now constructed, may provide critical insights into the origin of the new infection spikes and waves that are occurring as public health constraints are further relaxed, schools and colleges reopen, holidays occur, commercial air travel increases, and individuals change their behavior because of COVID-19 "fatigue." The genome data will also be useful in assessing ongoing molecular evolution in spike and other proteins as baseline herd immunity is generated, either by natural exposure to SARS-CoV-2 or by vaccination. The signal of potential selection contributing to some spike protein diversity and identification of naturally occurring mutant RBD variants with altered serologic recognition warrant close attention and expanded study.

Patient specimens. All specimens were obtained from individuals who were registered patients at Houston Methodist hospitals, associated facilities (e.g., urgent care centers), or institutions in the greater Houston metropolitan region that use our laboratory services. Virtually all individuals met the criteria specified by the Centers for Disease Control and Prevention to be classified as a person under investigation.

SARS-CoV-2 molecular diagnostic testing. Specimens obtained from symptomatic patients with a high degree of suspicion for COVID-19 disease were tested in the Molecular Diagnostics Laboratory at Houston Methodist Hospital using an assay granted Emergency Use Authorization (EUA) from the FDA (https://www.fda.gov/medical-devices/emergency-situations-medical-devices/faqs-diagnostic-testing-sa rs-cov-2#offeringtests). Multiple testing platforms were used, including an assay that follows the protocol published by the WHO (https://www.who.int/docs/default-source/coronaviruse/protocol-v2-1.pdf) using an EZ1 virus extraction kit and an EZ1 Advanced XL instrument or a QIASymphony DSP virus kit and a QIASymphony instrument for nucleic acid extraction and an ABI 7500 Fast Dx instrument with 7500 SDS software for reverse transcription RT-PCR, the COVID-19 test using BioFire Film Array 2.0 instruments, the Xpert Xpress SARS-CoV-2 test using Cepheid GeneXpert Infinity or Cepheid GeneXpert Xpress IV instruments, the SARS-CoV-2 assay using a Hologic Panther instrument, and the Aptima SARS-CoV-2 assay using a Hologic Panther Fusion system. All assays were performed according to the manufacturer's instructions. Testing was performed on material obtained from nasopharyngeal or oropharyngeal swabs immersed in universal transport media (UTM), bronchoalveolar lavage fluid, or sputum treated with dithiothreitol (DTT). To standardize specimen collection, an instructional video was created for Houston Methodist Hospital health care workers (https://vimeo.com/396996468/2228335d56).

Epidemiologic curve. The number of confirmed COVID-19-positive cases was obtained from USA-Facts.org (https://usafacts.org/visualizations/coronavirus-covid-19-spread-map/) for Austin, Brazoria, Chambers, Fort Bend, Galveston, Harris, Liberty, Montgomery, and Waller counties. COVID-19positive cases for Houston Methodist Hospital patients were obtained from our Laboratory Information System and plotted using the documented collection time.

SARS-CoV-2 genome sequencing. Libraries for whole-virus genome sequencing were prepared according to version 1 or version 3 of the ARTIC nCoV-2019 sequencing protocol (https://artic.network/ ncov-2019). Long reads were generated with the LSK-109 sequencing kit, 24 native barcodes (NBD104 and NBD114 kits), and a GridION instrument (Oxford Nanopore). Short reads were generated with a NexteraXT kit and a NextSeq 550 instrument (Illumina).

SARS-CoV-2 genome sequence analysis. Consensus virus genome sequences from the Houston area isolates were generated using the ARTIC nCoV-2019 bioinformatics pipeline. Publicly available genomes and metadata were acquired through GISAID on 19 August 2020. GISAID sequences containing greater than 1% N characters and Houston sequences with greater than 5% N characters were removed from consideration. Identical GISAID sequences originating from the same geographic location with the same collection date were also removed from consideration to reduce redundancy. Nucleotide sequence alignments for the combined Houston and GISAID strains were generated using MAFFT version 7.130b with default parameters (86) . Sequences were manually curated in JalView (87) to trim the ends and to remove sequences containing spurious inserts. Phylogenetic trees were generated using FastTree with the generalized time-reversible model for nucleotide sequences (88) . CLC Genomics Workbench (Qiagen) was used to generate the phylogenetic tree figures.

Geospatial mapping. The home address Zip code for all SARS-CoV-2-positive patients was used to generate the geospatial maps. To examine geographic relatedness among genetically similar isolates, geospatial maps were filtered for isolates containing specific amino acid changes.

Time series. Geospatial data were filtered into wave 1 (5 March 2020 to 11 May 2020) and wave 2 (12 May 2020 to 7 July 2020) time intervals to illustrate the spread of confirmed SARS-CoV-2-positive patients identified over time.

Machine learning. Virus genome alignments and patient metadata were used to build models to predict patient metadata and outcomes using both classification models and regression. Metadata considered for prediction in the classification models included age, ABO and Rh blood type, ethnic group, ethnicity, sex, ICU admission, IMU admission, supplemental oxygen use, and ventilator use. Metadata considered for prediction in regression analysis included ICU length of stay, IMU length of stay, total length of stay, supplemental oxygen use, and ventilator use. Because sex, blood type, Rh factor, age, age decade, ethnicity, and ethnic group are features in the patient features and combined feature sets, models were not trained for these labels using patient and combined feature sets. Additionally, age, Long et al.

length of stay, IMU length of stay, ICU length of stay, mechanical ventilation days, and supplemental oxygen days were treated as regression problems and XGBoost regressors were built while the rest were treated as classification problems and XGBoost classifiers were built.

Three types of features were considered for training the XGBoost classifiers: alignment features, patient features, and the combination of alignment and patient features. Alignment features were generated from the consensus genome alignment such that columns containing ambiguous nucleotide bases were removed to ensure that the models did not learn patterns from areas of low coverage. These alignments were then one-hot encoded to form the alignment features. Patient metadata values were one-hot encoded with the exception of age, which remained as a raw integer value, to create the patient features. These metadata values consisted of age, ABO, Rh blood type, ethnic group, ethnicity, and sex. All three types of feature sets were used to train models that predict ICU length of stay, IMU length of stay, overall length of stay, days of supplemental oxygen therapy, and days of ventilator usage, while only alignment features were used to train models that predict age, ABO, Rh blood type, ethnic group, ethnicity, and sex.

A 10-fold cross validation was used to train XGBoost models (89) as described previously (90, 91) . Depths of 4, 8, 16, 32, and 64 were used to tune the models, but the accuracies plateaued after a depth of 16. SciKit-Learn's (92) classification report and R 2 score were then used to access the overall accuracy of the classification and regression models, respectively.

Patient metadata correlations. We encoded values into multiple columns for each metadata field for patients if metadata was available. For example, the ABO column was divided into four columns for A, B, AB, and O blood type. Those columns were encoded with a 1 for the patients' ABO type, with all other columns encoded with 0. This was repeated for all nonoutcome metadata fields. Age, however, was not reencoded, as the raw integer values were used. Each column was then correlated to the various outcome values for each patient (deceased, ICU length, IMU length, length of stay, supplemental oxygen length, and ventilator length) to obtain a Pearson coefficient correlation value for each metadata label and outcome.

Analysis of the nsp12 polymerase and S protein genes. The nsp12 virus polymerase and S protein genes were analyzed by plotting SNP density in the consensus alignment using Python (Python v3.4.3, Biopython Package v1.72). The frequency of SNPs in the Houston isolates was assessed, along with amino acid changes for nonsynonymous SNPs.

Cycle threshold (C T ) comparison of SARS-CoV-2 strains with either Asp614 or Gly614 amino acid replacements in the spike protein. The cycle threshold (C T ) value for every sequenced strain that was detected from a patient specimen using the SARS-CoV-2 assay on a Hologic Panther instrument was retrieved from the Houston Methodist Hospital Laboratory Information System. The statistical significance of results of comparisons between the mean C T values for strains with an aspartate (n ϭ 102) or glycine (n ϭ 812) amino acid at position 614 of the spike protein was determined with the Mann-Whitney test (GraphPad Prism 8).

Creation and characterization of spike protein RBD variants. Spike RBD variants were cloned into the spike-6P (HexaPro; F817P, A892P, A899P, A942P, K986P, V987P) base construct that also includes the D614G substitution (pIF638). Briefly, a segment of the gene encoding the RBD was excised with EcoRI and NheI, mutagenized by PCR, and assembled with a HiFi DNA assembly cloning kit (NEB).

FreeStyle 293-F cells (Thermo Fisher Scientific) were cultured and maintained in a humidified atmosphere of 37°C and 8% CO 2 with shaking at 110 to 125 rpm. Cells were transfected with plasmids encoding spike protein variants using polyethylenimine. Three hours posttransfection, 5 M kifunensine was added to each culture. Cells were harvested 4 days after transfection, and the protein-containing supernatant was separated from the cells by two centrifugation steps: 10 min at 500 relative centrifugal force (rcf) and 20 min at 10,000 rcf. Supernatants were kept at 4°C throughout. Clarified supernatant was loaded on a Poly-Prep chromatography column (Bio-Rad) containing Strep-Tactin Superflow resin (IBA), washed with five column volumes (CV) of wash buffer (100 mM Tris-HCl [pH 8.0], 150 mM NaCl, 1 mM EDTA), and eluted with four CV of elution buffer (100 mM Tris-HCl [pH 8.0], 150 mM NaCl, 1 mM EDTA, 2.5 mM D-desthiobiotin). The eluate was spin concentrated (Amicon Ultra-15) to 600 l and further purified via size exclusion chromatography (SEC) using a Superose 6 Increase 10/300 column (GE) and SEC buffer (2 mM Tris [pH 8.0], 200 mM NaCl, 0.02% NaN 3 ). Proteins were concentrated to 300 l and stored in SEC buffer.

The RBD spike mutants chosen for analysis were all RBD amino acid mutants identified by our genome sequencing study as of 15 June 2020. We note that the exact boundaries of the RBD domain vary depending on the paper used as the reference. We used the boundaries demarcated in Fig. 1A Enzyme-linked immunosorbent assays. ELISAs were performed to characterize binding of S6P, S6P D614G, and S6P D614G-RBD variants to human ACE2 and the RBD-binding monoclonal antibody CR3022. The ACE2-hFc chimera was obtained from GenScript (Z03484), and the CR3022 antibody was purchased from Abcam (Ab273073). Corning 96-well high-binding plates (CLS9018BC) were coated with spike variants at 2 g/ml overnight at 4°C. After four washes with phosphate-buffered saline-0.1% Tween 20 (PBST; 300 l/well), plates were blocked with PBS-2% milk (PBSM) for 2 h at room temperature and again washed four times with PBST. These were serially diluted in PBSM 1:3 seven times in triplicate. After 1 h Two Waves of COVID-19 Disease in Houston, Texas ® of incubation at room temperature, plates were washed four times in PBST, labeled with 50 l mouse anti-human IgG1 Fc-HRP (SouthernBiotech, 9054-05) for 45 min in PBSM, and washed again in PBST before addition of 50 l 1-step Ultra TMB-ELISA substrate (Thermo Scientific, 34028). Reactions were developed for 15 min and stopped by addition of 50 l 4 M H 2 SO 4 . Absorbance intensity (450 nm) was normalized within a plate, and 50% effective concentration (EC 50 ) values were calculated through 4-parameter logistic curve (4PL) analysis using GraphPad Prism 8.4.3.

Supplemental material is available online only. 

World Health Organization coronavirus disease 2019 (COVID-19) situation report

The species Severe acute respiratory syndromerelated coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

A novel coronavirus outbreak of global health concern

Another decade, another coronavirus

Country-level factors associated with the early spread of COVID-19 cases at 5, 10 and 15 days since the onset

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

China Novel Coronavirus Investigating and Research Team. 2020. A novel coronavirus from patients with pneumonia in China

A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster

A new coronavirus associated with human respiratory disease in China

Cryptic transmission of SARS-CoV-2 in Washington State

Introductions and early spread of SARS-CoV-2 in the New York City area

COVID-19: data

Daily COVID-19 outbreak summary

Houston region grows more racially/ethnically diverse, with small declines in segregation. A joint report analyzing census data from

Molecular architecture of early dissemination and evolution of the SARS-CoV-2 virus in metropolitan

Characteristics and outcomes of COVID-19 patients during initial peak and resurgence in the Houston metropolitan area

Ebola virus glycoprotein with increased infectivity dominated the 2013-2016 epidemic

Human adaptation of Ebola virus during the West African outbreak

Functional characterization of adaptive mutations during the West African Ebola virus outbreak

Integrated analysis of population genomics, transcriptomics and virulence provides novel insights into Streptococcus pyogenes pathogenesis

Structure of the RNA-dependent RNA polymerase from COVID-19 virus

Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir

Remdesivir and SARS-CoV-2: structural requirements at both nsp12 RdRp and nsp14 exonuclease active-sites

Remdesivir is a direct-acting antiviral that inhibits RNAdependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency

Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease

Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection

Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2

Compassionate use of remdesivir for patients with severe Covid-19

Remdesivir for 5 or 10 days in patients with severe Covid-19

Remdesivir for the treatment of Covid-19 -preliminary report

Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial

Remdesivir for severe COVID-19 versus a cohort receiving standard of care

China National Center for Bioinformation (CNCB). 2019. Novel coronavirus resource

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein

Structural and functional basis of SARS-CoV-2 entry by using human ACE2

Beigel JH, mRNA-1273 Study Group. 2020. An mRNA vaccine against SARS-CoV-2 -preliminary report

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2

Broad neutralization of SARS-related viruses by human monoclonal antibodies

Potently neutralizing and protective human antibodies against SARS-CoV-2

Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition

REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies

A potently neutralizing antibody protects mice against SARS-CoV-2 infection

Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and receptor binding domain IgG correlate with virus neutralization

Treatment of COVID-19 patients with convalescent plasma reveals a signal of significantly decreased mortality

Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding

The receptor binding domain of SARS-CoV-2 spike is the key target of neutralizing antibody in human polyclonal sera

Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates

ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques

A human monoclonal antibody blocking SARS-CoV-2 infection

Human neutralizing antibodies elicited by SARS-CoV-2 infection

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

A SARS-CoV-2 infection model in mice demonstrates protection by neutralizing antibodies

SARS-CoV-2 infection protects against rechallenge in rhesus macaques

Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques

A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV

Structure-based design of prefusion-stabilized SARS-CoV-2 spikes

Developing a fully glycosylated fulllength SARS-CoV-2 Spike protein model in a viral membrane

Tracking changes in SARS-CoV-2 Spike: evidence that D614G increases infectivity of the COVID-19 virus

D614G mutation of SARS-CoV-2 spike protein enhances viral infectivity

A unique clade of SARS-CoV-2 viruses is associated with lower viral loads in patient upper airways

Comparing viral load and clinical outcomes in Washington State across D614G substitution in spike protein of SARS-CoV-2

Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity

Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody

Structural and functional analysis of the D614G SARS-CoV-2 spike protein variant

The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity

Neutralization of SARS-CoV-2 by destruction of the prefusion spike

Molecular architecture of early dissemination and evolution of the SARS-CoV-2 virus in metropolitan

Spike mutation D614G alters SARS-CoV-2 fitness and neutralization susceptibility

Phylogenetic analysis of SARS-CoV-2 in the Boston area highlights the role of recurrent importation and superspreading events

Spread of SARS-CoV-2 in the Icelandic population

Genomewide association study of severe Covid-19 with respiratory failure

The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic

Escape from neutralizing antibodies by SARS-CoV 2 spike protein variants

A key linear epitope for a potent neutralizing antibody to SARS-CoV-2 S-RBD

Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail

Population genomic analysis of 1,777 extendedspectrum beta-lactamase-producing Klebsiella pneumoniae isolates

Haemagglutinin mutations and glycosylation changes shaped the 2012/13 influenza A(H3N2) epidemic

MAFFT multiple sequence alignment software version 7: improvements in performance and usability

Jalview Version 2-a multiple sequence alignment editor and analysis workbench

FastTree 2-approximately maximum-likelihood trees for large alignments

XGBoost: a scalable tree boosting system

Developing an in silico minimum inhibitory concentration panel test for Klebsiella pneumoniae

Using machine learning to predict antimicrobial MICs and associated genomic features for nontyphoidal Salmonella

Scikit-learn: machine learning in Python

Distinct conformational states of SARS-CoV-2 spike protein

We thank Steven Hinrichs and colleagues at the Nebraska Public Health Laboratory and David Persse and colleagues at the Houston Health Department for providing samples used to validate our initial SARS-CoV-2 molecular assay. We thank Jessica Thomas and Zejuan Li, Erika Walker, Concepcion C. Cantu, the very talented and dedicated molecular technologists, and the many labor pool volunteers in the Molecular Diagnostics Laboratory for their dedication to patient care. We also thank Brandi Robinson, Harrold Cano, Cory Romero, Brooke Burns, and Hayder Mahmood for technical assistance. We are indebted to Marc Boom and Dirk Sostman for their support and to many very generous Houston philanthropists for their tremendous support of this ongoing project, including but not limited to an anonymous philanthropist, Ann and John Bookout III, Carolyn and John Bookout, Ting Tsung and the Wei Fong Chao Foundation, Ann and Leslie Doggett, Freeport LNG, the Hearst Foundations, the Jerold B. Katz Foundation, C. James and Carole Walter Looke, Diane and David Modesett, the Sherman Foundation, and Paula and Joseph C. "Rusty" Walter III. We gratefully acknowledge the originating and submitting laboratories of the SARS-CoV-2 genome sequences from GISAID's EpiFlu Database used in some of the work presented here. We also thank many colleagues for critical reading of the manuscript and suggesting improvements and Sasha Pejerrey, Adrienne Winston, Heather McConnell, and Kathryn Stockbauer for editorial contributions. We appreciate Stephen Schaffner for his helpful comments regarding the correlation analysis. We are especially indebted to Nancy Jenkins and Neal Copeland for their scholarly suggestions to improve an early version of the manuscript.